Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Tanja Stocks

Tanja Stocks

Researcher

Tanja Stocks

Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can)

Author

  • G. Nagel
  • H. Concin
  • T. Bjorge
  • K. Rapp
  • Jonas Manjer
  • G. Hallmans
  • G. Diem
  • C. Haggstrom
  • A. Engeland
  • Martin Almquist
  • H. Jonsson
  • R. Selmer
  • T. Stocks
  • S. Tretli
  • H. Ulmer
  • P. Stattin
  • A. Lukanova

Summary, in English

Background: Risk factors for rare gynecological cancers are largely unknown. Initial research has indicated that the metabolic syndrome (MetS) or individual components could play a role. Materials and methods: The Metabolic syndrome and Cancer project cohort includes 288 834 women. During an average follow-up of 11 years, 82 vulvar, 26 vaginal and 43 other rare gynecological cancers were identified. Hazard ratios (HRs) were estimated fitting Cox proportional hazards regression models for tertiles and standardized z-scores [with a mean of 0 and a standard deviation (SD) of 1] of body mass index (BMI), blood pressure, glucose, cholesterol, triglycerides and MetS. Risk estimates were corrected for random error in the measurement of metabolic factors. Results: The MetS was associated with increased risk of vulvar [HR 1.78, 95% confidence interval (CI) 1.30-2.41) and vaginal cancer (HR 1.87, 95% CI 1.07-3.25). Among separate MetS components, 1 SD increase in BMI was associated with overall risk (HR 1.43, 95% CI 1.23-1.66), vulvar (HR 1.36, 95% CI 1.11-1.69) and vaginal cancer (HR 1.79, 95% CI 1.30-2.46). Blood glucose and triglyceride concentrations were associated with increased risk of vulvar cancer (HR 1.98, 95% CI 1.10-3.58 and HR 2.09, 95% CI 1.39-3.15, respectively). Conclusion: The results from this first prospective study on rare gynecological cancers suggest that the MetS and its individual components may play a role in the development of these tumors.

Department/s

  • EpiHealth: Epidemiology for Health
  • Surgery

Publishing year

2011

Language

English

Pages

1339-1345

Publication/Series

Annals of Oncology

Volume

22

Issue

6

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Cancer and Oncology

Keywords

  • epidemiology
  • MetS
  • rare gynecological cancers

Status

Published

Research group

  • Surgery

ISBN/ISSN/Other

  • ISSN: 1569-8041